Harmacotherapy of schizophrenic patients: Achievements, unsolved needs, future research necessities

Current Pharmaceutical Biotechnology

Volumn 13, Issue 8, 2012, Pages 1476-1489

  Möller, Hans Jürgen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antipsychotics; Drug development; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BIFEPRUNOX; CANNABINOID 1 RECEPTOR ANTAGONIST; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; FIRST GENERATION ANTIPSYCHOTIC AGENT; GLUTAMATE RECEPTOR AGONIST; HALOPERIDOL; MUSCARINIC M1 RECEPTOR AGONIST; NEUROKININ 3 RECEPTOR ANTAGONIST; NEUROLEPTIC AGENT; OLANZAPINE; PECAZINE; PLACEBO; PROMAZINE; QUETIAPINE; RISPERIDONE; SECOND GENERATION ANTIPSYCHOTIC AGENT; SEROTONIN 2A ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTINDOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE;

AGRANULOCYTOSIS; ALOGIA; ANHEDONIA; ANTIADRENERGIC EFFECT; ANTICHOLINERGIC EFFECT; ANTISOCIAL BEHAVIOR; ARTICLE; ATTENTION DISTURBANCE; AVOLITION; BLUNTED AFFECT; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DELUSION; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; EFFECT SIZE; EXTRAPYRAMIDAL SYMPTOM; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HALLUCINATION; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPOTENSION; MENTAL DISEASE; MENTAL PERFORMANCE; METABOLIC DISORDER; MOLECULAR GENETICS; NEGATIVE SYNDROME; NEUROIMAGING; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PROBLEM SOLVING; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL COGNITION; SYMPTOMATOLOGY; TACHYCARDIA; THOUGHT DISORDER; TREATMENT REFUSAL; TREATMENT RESPONSE; VERBAL MEMORY; VISUAL MEMORY; WEIGHT GAIN; WORKING MEMORY; DEPRESSION; DRUG RESISTANCE; REVIEW;

ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER; DRUG RESISTANCE; HUMANS; SCHIZOPHRENIA;

EID: 84862621041     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800784907     Document Type: Article

References (149)

1. Häfner, H.; Ander Heiden, W. Course and Outcome. In: Clinical Handbook of Schizophrenia, Mueser, K., Jeste, D., Eds.; Guilford Press: New York, 2008; pp. 100-113.
2. Möller, H.J.; Jäger, M.; Riedel, M.; Obermeier, M.; Strauss, A.; Bottlender, R. The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: Results on the diagnostic classification and its predictive impact on long-term outcome. European Psychiatry, 2011,26(4), 231-243.
3. Möller, H.J. Systematic of psychiatric disorders between categorical and dimensional approaches: Kraepelin's dichotomy and beyond. Eur. Arch. Psychiatry Clin. Neurosci., 2008, 258, 48-73.
4. Möller, H.J.; Jäger, M.; Riedel, M.; Obermeier, M.; Strauss, A.; Bottlender, R. The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: Comparison of psychopathological and psychosocial course and outcome and prediction of chronicity. Eur. Arch. Psychiatry Clin. Neurosci., 2010,260(5), 367-384.
5. Bottlender, R.; Strauss, A.; Moller, H.J. Social disability in schizophrenic, schizoaffective and affective disorders 15 years after first admission. Schizophr. Res., 2010, 116, 9-15.
6. Möller Leimkühler, A. Multivariate prediction of relatives' stress outcome one year after first hospitalization of schizophrenic anddepressed patients. Eur. Arch. Psychiatry Clin. Neurosci., 2006, 256, 122-130.
7. Schennach-Wolff, R.; Jager, M.; Seemuller, F.; Obermeier, M.; Messer, T.; Laux, G.; Pfeiffer, H.; Naber, D.; Schmidt, L.G.; Gaebel, W.; Huff, W.; Heuser, I.; Maier, W.; Lemke, M.R.; Ruther, E.; Buchkremer, G.; Gastpar, M.; Moller, H.J.; Riedel, M. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. Schizophr. Res., 2009, 113, 210-217.
8. Koutsouleris, N.; Meisenzahl, E.M.; Davatzikos, C.; Bottlender, R.; Frodl, T.; Scheuerecker, J.; Schmitt, G.; Zetzsche, T.; Decker, P.; Reiser, M.; Moller, H.J.; Gaser, C. Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. Arch. Gen. Psychiatry, 2009, 66, 700-712.
9. Andreasen, N.C., Olsen, S. Negative v positive schizophrenia. Definition and validation. Arch. Gen. Psychiatry, 1982, 39, 789-794.
10. Crow, T.J. The two-syndrome concept: origins and current status. Schizophr. Bull., 1985, 11, 471-486.
11. Green, M.F. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry, 1996, 153, 321-330.
12. Harvey, P.D.; Keefe, R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry, 2001, 158, 176-184.
13. Robinson, D.G.; Woerner, M.G.; Alvir, J.M.; Geisler, S.; Koreen, A.; Sheitman, B.; Chakos, M.; Mayerhoff, D.; Bilder, R.; Goldman, R.; Lieberman, J.A. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry, 1999, 156, 544-549.
14. Fenton, W.S.; McGlashan, T.H. Prognostic scale for chronic schizophrenia. Schizophr. Bull., 1987, 13, 277-286.
15. Hegarty, J.D.; Baldessarini, R.J.; Tohen, M.; Waternaux, C.; Oepen, G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am. J. Psychiatry, 1994, 151, 1409-1416.
16. McGlashan, T.H.; Fenton, W.S. Subtype progression and pathophysiologic deterioration in early schizophrenia. Schizophr. Bull., 1993, 19, 71-84.
17. Möller, H.J.; Bottlender, R.; Groß, A.; Hoff, P.; Wittmann, J.; Wegner, U.; Strauss, A. The Kraepelinian dichotomy: preliminary results of a 15-year follow-up study on functional psychoses: focus on negative symptoms. Schizophr. Res., 2002, 56, 87-94.
18. Albus, M.; Hubmann, W.; Mohr, F.; Hecht, S.; Hinterberger- Weber, P.; Seitz, N.N.; Kuchenhoff, H. Neurocognitive functioning in patients with first-episode schizophrenia: results of a prospective 5-year follow-up study. Eur. Arch. Psychiatry Clin. Neurosci., 2006, 256, 442-451.
19. Keefe, R.S.; Harvey, P.D. Implementation considerations for multisite clinical trials with cognitive neuroscience tasks. Schizophr. Bull., 2008, 34, 656-663.
20. Davidson, M.; Galderisi, S.; Weiser, M.; Werbeloff, N.; Fleischhacker, W.W.; Keefe, R.S.; Boter, H.; Keet, I.P.; Prelipceanu, D.; Rybakowski, J.K.; Libiger, J.; Hummer, M.; Dollfus, S.; Lopez- Ibor, J.J.; Hranov, L.G.; Gaebel, W.; Peuskens, J.; Lindefors, N.; Riecher-Rossler, A.; Kahn, R.S. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am. J. Psychiatry, 2009, 166, 675-682.
21. Davidson, L.; McGlashan, T.H. The varied outcomes of schizophrenia. Can. J. Psychiatry, 1997, 42, 34-43.
22. Bottlender, R.; Strauß, A.; Möller, H.J. Impact of duration of symptoms prior to first hospitalization on acute outcome in 998 schizophrenic patients. Schizophr. Res., 2000, 44, 145-150.
23. Bottlender, R.; Sato, T.; Jäger, M.; Groll, C.; Strauß, A.; Möller, H.J. The impact of duration of untreated psychosis and premorbid functioning on outcome of first inpatient treatment in schizophrenic and schizoaffective patients. Eur. Arch. Psychiatry Clin. Neurosci., 2002, 252, 226-231.
24. Bottlender, R.; Sato, T.; Jager, M.; Wegener, U.; Wittmann, J.; Strauss, A.; Möller, H.J. The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia. Schizophr. Res., 62, 37-44.
25. Jäger, M.; Riedel, M.; Messer, T.; Laux, G.; Pfeiffer, H.; Naber, D.; Schmidt, L.G.; Gaebel, W.; Huff, W.; Heuser, I.; Kuhn, K.U.; Lemke, M.R.; Ruther, E.; Buchkremer, G.; Gastpar, M.; Bottlender, R.; Strauss, A.; Moller, H.J. Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. Eur. Arch. Psychiatry Clin. Neurosci., 2007, 257, 47-53.
26. Murray, R.M.; Fearon, P. The developmental 'risk factor' model of schizophrenia. J. Psychiatr. Res., 1999, 33, 497-499.
27. Marenco, S.; Weinberger, D.R. The neuro developmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev. Psychopathol., 2000, 12, 501-527.
28. Maier, W. Common risk genes for affective and schizophrenic psychoses. Eur. Arch. Psychiatry Clin. Neurosci., 2008, 258 (Suppl. 2), 37-40.
29. Rujescu, D.; Ingason, A.; Cichon, S.; Pietilainen, O.P.; Barnes, M.R.; Toulopoulou, T.; Picchioni, M.; Vassos, E.; Ettinger, U.; Bramon, E.; Murray, R.; Ruggeri, M.; Tosato, S.; Bonetto, C.; Steinberg, S.; Sigurdsson, E.; Sigmundsson, T.; Petursson, H.; Gylfason, A.; Olason, P.I.; Hardarsson, G.; Jonsdottir, G.A.; Gustafsson, O.; Fossdal, R.; Giegling, I.; Moller, H.J.; Hartmann, A.M.; Hoffmann, P.; Crombie, C.; Fraser, G.; Walker, N.; Lonnqvist, J.; Suvisaari, J.; Tuulio-Henriksson, A.; Djurovic, S.; Melle, I.; Andreassen, O.A.; Hansen, T.; Werge, T.; Kiemeney, L.A.; Franke, B.; Veltman, J.; Buizer-Voskamp, J.E.; Sabatti, C.; Ophoff, R.A.; Rietschel, M.; Nothen, M.M.; Stefansson, K.; Peltonen, L.; St Clair, D.; Stefansson, H.; Collier, D.A. Disruption of the neurexin 1 gene is associated with schizophrenia. Hum. Mol. Genet., 2009, 18, 988-996.
30. Stefansson, H.; Ophoff, R.A.; Steinberg, S.; Andreassen, O.A.; Cichon, S.; Rujescu, D.; Werge, T.; Pietilainen, O.P.; Mors, O.; Mortensen, P.B.; Sigurdsson, E.; Gustafsson, O.; Nyegaard, M.; Tuulio Henriksson, A.; Ingason, A.; Hansen, T.; Suvisaari, J.; Lonnqvist, J.; Paunio, T.; Borglum, A.D.; Hartmann, A.; Fink-Jensen, A.; Nordentoft, M.; Hougaard, D.; Norgaard-Pedersen, B. Bottcher, Y.; Olesen, J.; Breuer, R.; Moller, H.J.; Giegling, I.; Rasmussen, H.B.; Timm, S.; Mattheisen, M.; Bitter, I.; Rethelyi, J.M.; Magnusdottir, B.B.; Sigmundsson, T.; Olason, P.; Masson, G.; Gulcher, J.R.; Haraldsson, M.; Fossdal, R.; Thorgeirsson, T.E.; Thorsteinsdottir, U.; Ruggeri, M.; Tosato, S.; Franke, B.; Strengman, E.; Kiemeney, L.A.; Melle, I.; Djurovic, S.; Abramova, L.; Kaleda, V.; Sanjuan, J.; de Frutos, R.; Bramon, E.; Vassos, E.; Fraser, G.; Ettinger, U.; Picchioni, M.; Walker, N.; Toulopoulou, T.; Need, A.C.; Ge, D.; Yoon, J.L.; Shianna, K.V.; Freimer, N.B.; Cantor, R.M.; Murray, R.; Kong, A.; Golimbet, V.; Carracedo, A.; Arango, C.; Costas, J.; Jonsson, E.G.; Terenius, L.; Agartz, I.; Petursson, H.; Nothen, M.M.; Rietschel, M.; Matthews, P.M.; Muglia, P.; Peltonen, L.; St Clair, D.; Goldstein, D.B.; Stefansson, K.; Collier, D.A. Common variants conferring risk of schizophrenia. Nature, 2009, 460, 744-747.
31. Cahn, W.; Van Haren, N.E.; Hulshoff Pol, H.E.; Schnack, H.G.; Caspers, E.; Laponder, D.A.; Kahn, R.S. Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. Br. J. Psychiatry, 2006, 189, 381-382.
32. Koutsouleris, N.; Schmitt, G.J.; Gaser, C.; Bottlender, R.; Scheuerecker, J.; McGuire, P.; Burgermeister, B.; Born, C.; Reiser, M.; Moller, H.J.; Meisenzahl, E.M. Neuroanatomical correlates of different vulnerability states for psychosis and their clinical outcomes. Br. J. Psychiatry, 2009, 195, 218-226.
33. Lieberman, J.A.; Tollefson, G.D.; Charles, C.; Zipursky, R.; Sharma, T.; Kahn, R.S.; Keefe, R.S.; Green, A.I.; Gur, R.E.; McEvoy, J.; Perkins, D.; Hamer, R.M.; Gu, H.; Tohen, M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry, 2005, 62, 361-370.
34. Sedvall, G.; Farde, L. Chemical brain anatomy in schizophrenia. Lancet, 1995, 346, 743-749.
35. Möller, H.J. Management of the negative symptoms of schizophrenia. New treatment options. CNS Drugs, 2003, 17, 793-823.
36. Nuechterlein, K.H.; Dawson, M.E. A heuristic vulnerability/stress model of schizophrenic episodes. Schizophr. Bull., 1984, 10, 300-312.
37. Falkai, P.; Wobrock, T.; Lieberman, J.; Glenthoj, B.; Gattaz, W.F.; Möller, H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J. Biol. Psychiatry, 2005, 6, 132-191.
38. Falkai, P.; Wobrock, T.; Lieberman, J.; Glenthoj, B.; Gattaz, W.F.; Möller, H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J. Biol. Psychiatry, 2006, 7, 5-40.
39. Creese, I.; Burt, D.R.; Snyder, S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of anti schizophrenic drugs. Science, 1976, 192, 481-483.
40. Möller, H.J. Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuro leptics: methodological issues and clinical consequences. World J. Biol. Psychiatry, 2000, 1, 75-91.
41. Fleischhacker, W.W. Second generation antipsychotics. Psychopharmacology (Berl.), 2002, 162, 90-91.
42. Guttmacher, M. Phenothiazine Treatment in Acute Schizophrenia; Effectiveness: The National Institute of Mental Health Psychopharmacology Service Center Collaborative Study Group. Arch. Gen. Psychiatry, 1964, 10, 246-261.
43. Davis, J.; Barter, J.; Kane, J. Antipsychotic drugs. In: Comprehensive Textbook of Psychiatry. Kaplan, H.; Sadock, B.; Eds.; Williams &Wilkins: Baltimore, 1989; pp. 1591-1626.
44. Davis, J.M. Overview: maintenance therapy in psychiatry: I. Schizophrenia. Am. J. Psychiatry, 1975, 132, 1237-1245.
45. Kane, J.M. Dose selection and comparator drugs in schizophrenia research. J. Clin. Psychiatry, 2001, 62(Suppl. 9), 29-32; discussion 33-4.:29-32
46. Leucht, S.; Barnes, T.; Kissling, W.; Engel, R.; Kane, J.M. Relapse prevention in schizophrenia with new antipsychotics: a metaanalysis of randomized controlled trials. Am. J. Psychiatry, 2003, 160, 1209-1222.
47. Joy, C.B.; Adams, C.E.; Lawrie, S.M. Haloperidol versus placebo for schizophrenia. Cochrane Database Syst. Rev., 2006, (4), CD003082
48. Thornley, B.; Adams, C.E.; Awad, G. Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst. Rev., 2000, (2), CD000284
49. Awad, A.G.; Voruganti, L.N. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs, 2004, 18, 877-893.
50. Kapur, S.; Remington, G. Atypical antipsychotics. BMJ, 2000, 321, 1360-1361.
51. Möller, H.J.; Riedel, M. Side effect burden of antipsychotic medication. In: Schizophrenia Biopsychosocial Approaches and Current Challenges; Kasper, S., Papadimitriou, G.N., Eds.; Informa Healthcare: London, 2009; pp. 231-259.
52. Möller, H.J. Novel antipsychotics in the long-term treatment of schizophrenia. World J. Biol. Psychiatry, 2004, 5, 9-19.
53. Leucht, S.; Corves, C.; Arbter, D.; Engel, R.R.; Li, C.; Davis, J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 2009, 373, 31-41.
54. Tandon, R.; Belmaker, R.H.; Gattaz, W.F.; Lopez-Ibor, J.J. Jr.; Okasha, A.; Singh, B.; Stein, D.J.; Olie, J.P.; Fleischhacker, W.W.; Moeller, H.J. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr. Res., 2008, 100, 20-38.
55. Möller, H.J., Maier, W. Evidence-based medicine in psychotherapy: possibilities, problems and limitations. Eur. Arch. Psychiatry Clin. Neurosci., 2010, 260, 25-39.
56. Sartorius, N.; Fleischhacker, W.W.; Gjerris, A.; Kern, U.; Knapp, M.; Leonhard, B.; Lieberman, A.; Lopez-Ibor, J.J.; van Raay, B.; Tornquist, E., Twomey, E. The usefulness and use of secondgeneration antipsychotics - an update. Curr. Opin. Psychiatry, 2002, 15, 1-51.
57. Geddes, J.; Freemantle, N.; Harrison, P.; Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ, 2000, 321, 1371-1376.
58. Davis, J.M.; Chen, N.; Glick, I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry, 2003, 60, 553-564.
59. Leucht, S.; Pitschel-Walz, G.; Abraham, D.; Kissling, W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res., 1999, 35, 51-68.
60. Leucht, S.; Wahlbeck, K.; Hamann, J.; Kissling, W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet, 2003, 361, 1581-1589.
61. Möller, H.J.; Riedel, M.; Jager, M.; Wickelmaier, F.; Maier, W.; Kuhn, K.U.; Buchkremer, G.; Heuser, I.; Klosterkotter, J.; Gastpar, M.; Braus, D.F.; Schlosser, R.; Schneider, F.; Ohmann, C.; Riesbeck, M.; Gaebel, W. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int. J. Neuropsychopharmacol., 2008, 11, 985-997.
62. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. 2nd ed. Am. J. Psychiatry, 2004, 161(Suppl. 2), 1-114.
63. De Hert, M.; Dekker, J.; Wood, D.; Kahl, K.; Möller, H.J. Cardiovascular disease and diabetes in people with severe mental illness: Position Statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur. Psychiatry, 2009, 24, 412-424.
64. Brenner, H.D.; Dencker, S.J.; Goldstein, M.J.; Hubbard, J.W.; Keegan, D.L.; Kruger, G.; Kulhanek, F.; Liberman, R.P.; Malm, U.; Midha, K.K. Defining treatment refractoriness in schizophrenia. Schizophr. Bull., 1990, 16, 551-561.
65. Essock, S.M., Hargreaves, W.A.; Covell, N.H.; Goethe, J. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol. Bull., 1996, 32, 683-697.
66. Helgason, L. Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented? Acta. Psychiatr. Scand., 1990, 81, 231-235.
67. Kane, J.M.; Honigfeld, G.; Singer, J.; Meltzer, H. Clozapine in treatment-resistant schizophrenics. Psychopharmacol. Bull., 1988, 24, 62-67.
68. Chakos, M.; Lieberman, J.; Hoffman, E., Bradford, D.; Sheitman, B. Effectiveness of second-generation anti psychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry, 2001, 158, 518-526.
69. Breier, A.; Hamilton, S.H. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol. Psychiatry, 1999, 45, 403-411.
70. McEvoy, J.P.; Lieberman, J.A.; Stroup, T.S.; Davis, S.M.; Meltzer, H.Y.; Rosenheck, R.A.; Swartz, M.S.; Perkins, D.O.; Keefe, R.S.; Davis, C.E.; Severe, J.; Hsiao, J.K. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry, 2006, 163, 600-610.
71. Volavka, J.; Czobor, P.; Sheitman, B.; Lindenmayer, J.P.; Citrome, L.; McEvoy, J.P.; Cooper, T.B.; Chakos, M.; Lieberman, J. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry, 2002, 159, 255-262.
72. Jäger, M.; Messer, T.; Laux, G.; Pfeiffer, H.; Naber, D.; Schmidt, L.G.; Gaebel, W.; Klosterkotter, J.; Heuser, I.; Maier, W.; Lemke, M.R.; Ruther, E.; Buchkremer, G.; Gastpar, M.; Riedel, M.; Bottlender, R.; Strauss, A.; Moller, H.J. Standardized remission criteria in schizophrenia: descriptive validity and comparability with previously used outcome measures. Pharmacopsychiatry, 2008, 41, 190-195.
73. Jäger, M.; Riedel, M.; Schmauss, M.; Laux, G.; Pfeiffer, H.; Naber, D.; Schmidt, L.G.; Gaebel, W.; Klosterkotter, J.; Heuser, I.; Kuhn, K.U.; Lemke, M.R.; Ruther, E.; Buchkremer, G.; Gastpar, M.; Bottlender, R.; Strauss, A.; Moller, H.J. Prediction of symptom remission in schizophrenia during inpatient treatment. World J. Biol. Psychiatry, 2009, 10, 426-434.
74. Möller, H.J. Clinical evaluation of negative symptoms in schizophrenia. Eur. Psychiatry, 2007, 22, 380-386.
75. Carpenter, W.T. Jr.; Heinrichs, D.W.; Alphs, L.D. Treatment of negative symptoms. Schizophr. Bull., 1985, 11, 440-452.
76. Maier, W.; Möller, H.J. Meta-analyses: a method to maximise the evidence from clinical studies? Eur. Arch. Psychiatry Clin. Neurosci., 2010, 260, 17-23.
77. Meltzer, H.Y. Dopamine and negative symptoms in schizophrenia: critique of the type I-II hypothesis. In: Controversies in schizophrenia; Alpert, M., Ed.; Guilford: New York; 1985; pp. 110-136.
78. van Kammen, D.P.; Hommer, D.W.; Malas, K.L. Effect of pimozide on positive and negative symptoms in schizophrenic patients: are negative symptoms state dependent? Neuropsychobiology, 1987, 18, 113-117.
79. Möller, HJ.; Müller, H.; Borison, R.L.; Schooler N.R; Chouinard, G. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur. Arch. Psychiatry Clin. Neurosci., 1995, 245, 45-49.
80. Marder, S.R.; Meibach, R.C. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry, 1994, 151, 825-835.
81. Tollefson, G.D.; Birkett, M.A.; Kiesler, G.M.; Wood, A.J. Doubleblind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol. Psychiatry, 2001, 49, 52-63.
82. Möller, H.J.; van Praag, H.M.; Aufdembrinke, B.; Bailey, P.; Barnes, T.R.; Beck, J.; Bentsen, H.; Eich, F.X.; Farrow, L.; Fleischhacker, W.W.; Gerlach, J.; Grafford, K.; Hentschel, B.; Hertkorn, A.; Heylen, S.; Lecrubier, Y.; Leonhard, J.P.; McKenna, P.; Maier, W.; Pedersen, V.; Rappard, A.; Rein, W.; Ryan, J.; Sloth Nielsen, M.; Stieglitz, R.D.; Wegener, G.; Wilson, J. Negative symptoms in schizophrenia: considerations for clinical trials Working group on negative symptoms in schizophrenia. Psychopharmacology, 1994, 115, 221-228.
83. The European Agency for the Evaluation of Medicinal Products: Note for Guidance on the Clinical Investigation of Medicinal Products in the Treatment of Schizophrenia. London, 1998.
84. Loo, H.; Poirier-Littre, M.F.; Theron, M.; Rein, W.; Fleurot, O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br. J. Psychiatry, 1997, 170, 18-22.
85. Juckel, G.; Schlagenhauf, F.; Koslowski, M.; Filonov, D.; Wustenberg, T.; Villringer, A.; Knutson, B.; Kienast, T.; Gallinat, J.; Wrase, J.; Heinz, A. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (Berl.), 2006, 187, 222-228.
86. Cassens, G.; Inglis, A.K.; Appelbaum, P.S.; Gutheil, T.G. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr. Bull., 1990, 16, 477-499.
87. Sharma, T. Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br. J. Psychiatry Suppl., 1999, (38), 44-51.
88. Weiss, E.M.; Bilder, R.M.; Fleischhacker, W.W. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia. Psychopharmacology (Berl.), 2002, 162, 11-17.
89. Bilder, R.M.; Goldman, R.S.; Volavka, J.; Czobor, P.; Hoptman, M.; Sheitman, B.; Lindenmayer, J.P.; Citrome, L.; McEvoy, J.; Kunz, M.; Chakos, M.; Cooper, T.B.; Horowitz, T.L.; Lieberman, J.A. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry, 2002, 159, 1018-1028.
90. Harvey, P.D.; Siu, C.O.; Romano, S. Randomized, controlled,double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology (Berl.), 2004, 172, 324-332.
91. Green, M.F.; Marder, S.R.; Glynn, S.M.; McGurk, S.R.; Wirshing, W.C.; Wirshing, D.A.; Liberman, R.P.; Mintz, J. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol. Psychiatry, 2002, 51, 972-978.
92. Keefe, R.S.; Seidman, L.J.; Christensen, B.K.; Hamer, R.M.; Sharma, T.; Sitskoorn, M.M.; Lewine, R.R.; Yurgelun-Todd, D.A.; Gur, R.C.; Tohen, M.; Tollefson, G.D.; Sanger, T.M.; Lieberman, J.A. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am. J. Psychiatry, 2004, 161, 985-995.
93. Woodward, N.D.; Purdon, S.E.; Meltzer, H.Y.; Zald, D.H. A metaanalysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol., 2005, 8, 457-472.
94. Brunnauer, A.; Laux, G.; Geiger, E.; Moller, H.J. The impact of antipsychotics on psychomotor performance with regards to car driving skills. J. Clin. Psychopharmacol., 2004, 24, 155-160.
95. Soyka, M.; Winter, C.; Kagerer, S.; Brunnauer, M.; Laux, G.; Moller, H.J. Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls. J. Psychiatr. Res., 2005, 39, 101-108.
96. Meisenzahl, E.M.; Scheuerecker, J.; Zipse, M.; Ufer, S.; Wiesmann, M.; Frodl, T.; Koutsouleris, N.; Zetzsche, T.; Schmitt, G.; Riedel, M.; Spellmann, I.; Dehning, S.; Linn, J.; Bruckmann, H.; Moller, H.J. Effects of treatment with the atypical neuroleptic quetiapine on working memory function: a functional MRI followup investigation. Eur. Arch. Psychiatry Clin. Neurosci., 2006, 256, 522-531.
97. Braus, D.F.; Brassen, S. Functional magnetic resonance imaging and antipsychotics. Overview and own data. Radiologe, 2005, 45, 178-185.
98. Ettinger, U.; Williams, S.; Fannon, D.; Premkumar, P.; Kuipers, E.; Möller, H.J.; Kumari, V. Functional Magnetic Resonance Imaging of a Parametric Working Memory Task in Schizophrenia: Relationship with Performance and Effects of Antipsychotic Treatment. Int. J. Neuropsychopharmacol., 2010,216(1), 17-27.
99. Freudenreich, O.; Herz, L.; Deckersbach, T.; Evins, A.E.; Henderson, D.C.; Cather, C.; Goff, D.C. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl.), 2005, 181, 358-363.
100. Friedman, J.I.; Adler, D.N.; Howanitz, E.; Harvey, P.D.; Brenner, G.; Temporini, H.; White, L.; Parrella, M.; Davis, K.L. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol. Psychiatry, 2002, 51, 349-357.
101. Buchanan, R.W.; Summerfelt, A.; Tek, C.; Gold, J. An openlabeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr. Res., 2003, 59, 29-33.
102. Stryjer, R.; Strous, R.D.; Bar, F.; Werber, E.; Shaked, G.; Buhiri, Y.; Kotler, M.; Weizman, A.; Rabey, J.M. Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clin. Neuropharmacol., 2003, 26, 12-17.
103. Mendelsohn, E.; Rosenthal, M.; Bohiri, Y.; Werber, E.; Kotler, M.; Strous, R.D. Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living. Int. Clin. Psychopharmacol., 2004, 19, 319-324.
104. Allain, H.; Bentue-Ferrer, D.; Tribut, O.; Gauthier, S.; Michel, B.F.; Drieu-La Rochelle, C. Alzheimer's disease: the pharmacological pathway. Fundam. Clin. Pharmacol., 2003, 17, 419-428.
105. Tugal, O.; Yazici, K.M.; Anil Yagcioglu, A.E.; Gogus, A. A double- blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int. J. Neuropsychopharmacol., 2004, 7, 117-123.
106. Lenzi, A.; Maltinti, E.; Poggi, E.; Fabrizio, L.; Coli, E. Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia. Clin. Neuropharmacol., 2003, 26, 317-321.
107. Siris, S.G. Depression in schizophrenia: perspective in the era of Atypical antipsychotic agents. Am. J. Psychiatry, 2000, 157, 1379-1389.
108. Möller, H.J. Occurrence and treatment of depressive comorbidity cosyndromality in schizophrenic psychoses: conceptual and treatment issues. World J. Biol. Psychiatry, 2005, 6, 247-263.
109. Möller, H.J. Drug treatment of depressive symptoms in schizophrenia. Clinical Schizophrenia & Related Psychoses, 2008, 1, 328-340.
110. Jäger, M.; Riedel, M.; Schmauss, M.; Pfeiffer, H.; Laux, G.; Naber, D.; Gaebel, W.; Huff, W.; Schmidt, L.G.; Heuser, I.; Buchkremer, G.; Kuhn, K.U.; Ruther, E.; Hoff, P.; Gastpar, M.; Bottlender, R.; Strauss, A.; Moller, H.J. Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response. Psychiatry Res., 2008, 158, 297-305.
111. Dufresne, R.L.; Valentino, D.; Kass, D.J. Thioridazine improves affective symptoms in schizophrenic patients. Psychopharmacol. Bull., 1993, 29, 249-255.
112. Peuskens, J.; Van Baelen, B.; De Smedt, C.; Lemmens, P. Effects of risperidone on affective symptoms in patients with schizophrenia. Int. Clin. Psychopharmacol., 2000, 15, 343-349.
113. Möller, H.J. Ant depressive effects of traditional and second generation antipsychotics: a review of the clinical data. Eur. Arch. Psychiatry Clin. Neurosci., 2005, 255, 83-93.
114. Cruz, N.; Sanchez-Moreno, J.; Torres, F.; Goikolea, J.M.; Valenti, M.; Vieta, E. Efficacy of modern antipsychotics in placebocontrolled trials in bipolar depression: a meta-analysis. Int. J. Neuropsychopharmacol., 2010, 13, 5-14.
115. Bobo, W.V.; Shelton, R.C. Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data. Expert Opin. Pharmacother., 2009, 10, 2145-2159.
116. Calabrese, J.R.; Keck, P.E. Jr.; Macfadden, W.; Minkwitz, M.; Ketter, T.A.; Weisler, R.H.; Cutler, A.J.; McCoy, R.; Wilson, E.; Mullen, J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am. J. Psychiatry, 2005, 162, 1351-1360.
117. Thase, M.E.; Macfadden, W.; Weisler, R.H.; Chang, W.; Paulsson, B.; Khan, A.; Calabrese, J.R. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J. Clin. Psychopharmacol., 2006, 26, 600-609.
118. Tohen, M.; Vieta, E.; Calabrese, J.; Ketter, T.A.; Sachs, G.; Bowden, C.; Mitchell, P.B.; Centorrino, F.; Risser, R.; Baker, R.W.; Evans, A.R.; Beymer, K.; Dube, S.; Tollefson, G.D.; Breier, A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry, 2003, 60, 1079-1088.
119. Möller, H.J. Antipsychotic and anti depressive effects of second generation antipsychotics Two different pharmacological mechanisms? Eur. Arch. Psychiatry Clin. Neurosci., 2005, 255, 190-201.
120. Tollefson, G.D.; Sanger, T.M.; Beasley, C.M.; Tran, P.V. A double- blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol. Psychiatry, 1998, 43, 803-810.
121. Tollefson, G.D.; Sanger, T.M.; Lu, Y.; Thieme, M.E. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch. Gen. Psychiatry, 1998, 55, 250-258.
122. Emsley, R.A.; Buckley, P.; Jones, A.M.; Greenwood, M.R. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J. Psychopharmacol.; 17, 210-215.
123. Müller, N. COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr. Opin. Investig. Drugs, 2010, 11, 31-42.
124. Müller, N.; Riedel, M.; Schwarz, M.J. Psychotropic effects of COX-2 inhibitors--a possible new approach for the treatment of psychiatric disorders. Pharmacopsychiatry, 2004, 37, 266-269.
125. Müller, N.; Strassnig, M.; Schwarz, M.J.; Ulmschneider, M.; Riedel, M. COX-2 inhibitors as adjunctive therapy in schizophrenia. Expert. Opin. Investig. Drugs, 2004, 13, 1033-1044.
126. Möller, H.J. Course and long-term treatment of schizophrenic psychoses. Pharmacopsychiatry, 2004, 37(Suppl. 2), 126-135.
127. Möller, H.J. State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotic. World J. Biol. Psychiatry, 2000, 1, 204-214.
128. Cramer, J.A.; Rosenheck, R. Compliance with medication regimens for mental and physical disorders. Psychiatr. Serv., 1998, 49, 196-201.
129. Oehl, M.; Hummer, M.; Fleischhacker, W.W. Compliance with antipsychotic treatment. Acta. Psychiatr. Scand. Suppl., 2000, 102, 83-86.
130. Leucht, S.; Busch, R.; Hamann, J.; Kissling, W.; Kane, J.M. Earlyonset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol. Psychiatry, 2005, 57, 1543-1549.
131. Weiden, P.J.; Olfson, M. Cost of relapse in schizophrenia. Schizophr. Bull., 1995, 21, 419-429.
132. Bhanji, N.H.; Chouinard, G.; Margolese, H.C. A review of compliance,depot intramuscular antipsychotics and the new long-actinginjectable atypical antipsychotic risperidone in schizophrenia. Eur. Neuropsychopharmacol., 2004, 14, 87-92.
133. Dolder, C.R.; Lacro, J.P.; Dunn, L.B.; Jeste, D.V. Antipsychotic medication adherence: is there a difference between typical and atypical agents? American Journal of Psychiatry, 2002, 159, 103-108.
134. Kane, J.M. Dosing issues and depot medication in the maintenance treatment of schizophrenia. Int. Clin. Psychopharmacol., 1995, 10(Suppl. 3), 65-71.
135. Möller, H.J. Long-acting risperidone: focus on safety. Clin. Ther., 2006, 28, 633-651.
136. Möller, H.J. Long-acting in ject able risperidone for the treatment of schizophrenia: clinical perspectives. Drugs, 2007, 67, 1541-1566.
137. Kahn, R.S.; Fleischhacker, W.W.; Boter, H.; Davidson, M.; Vergouwe, Y.; Keet, I.P.; Gheorghe, M.D.; Rybakowski, J.K.; Galderisi, S.; Libiger, J.; Hummer, M.; Dollfus, S.; Lopez-Ibor, J.J.; Hranov, L.G.; Gaebel, W.; Peuskens, J.; Lindefors, N.; Riecher- Rossler, A.; Grobbee, D.E. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet, 2008, 371, 1085-1097.
138. Lieberman, J.A.; Tollefson, G.; Tohen, M.; Green, A.I.; Gur, R.E.; Kahn, R.; McEvoy, J.; Perkins, D.; Sharma, T.; Zipursky, R.; Wei, H.; Hamer, R.M. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am. J. Psychiatry, 2003, 160, 1396-1404.
139. Bishara, D.; Taylor, D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs, 2008, 68, 2269-2292.
140. Agid, O.; Kapur, S.; Remington, G. Emerging drugs for schizophrenia. Expert. Opin. Emerg. Drugs, 2008, 13, 479-495.
141. Laughren, T.; Levin, R. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr. Bull., 2006, 32, 220-222.
142. Kapur, S.; Mamo, D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003, 27, 1081-1090.
143. Gray, J.A.; Roth, B.L. The pipeline and future of drug development in schizophrenia. Mol. Psychiatry, 2007, 12, 904-922.
144. Insel, T.R.; Scolnick, E.M. Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol. Psychiatry, 2006, 11, 11-17.
145. Sawa, A.; Snyder, S.H. Schizophrenia: neural mechanisms for novel therapies. Mol. Med., 2003, 9, 3-9.
146. Miyamoto, S.; Duncan, G.E.; Marx, C.E.; Lieberman, J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry, 2005, 10, 79-104.
147. Arranz, M.J.; Kerwin, R.W. Advances in the pharmacogenetic prediction of antipsychotic response. Toxicology, 2003, 192, 33-35.
148. Arranz, M.J.; Munro, J.; Birkett, J.; Bolonna, A.; Mancama, D.; Sodhi, M.; Lesch, K.P.; Meyer, J.F.; Sham, P.; Collier, D.A.; Murray, R.M.; Kerwin, R.W. Pharmacogenetic prediction of clozapine response. Lancet, 2000, 355, 1615-1616.
149. Arranz, M.J.; de Leon, J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry, 2007, 12, 707-747.